Posted in | News | Nanobusiness

Will Nanotechnology Drive a New Innovation Economy for the U.S.

The current economic downturn highlights the importance - and challenges - of building a new 21st century "innovation economy" for America. To move beyond the current crisis, we need to retain and create advanced manufacturing and knowledge-intensive jobs, invest in "green" science and engineering research, and ensure the competitiveness of U.S. technology based industries and workers.

Nanotechnology—which some scientists and business leaders hail as ushering in the next technology-driven Industrial Revolution—promises to be one of the critical foundations for this new innovation economy. Nanotechnology is still early in its development cycle, although a variety of nano-enabled products are already on the world market in clothing, cosmetics, washing machines, and sports equipment. Numerous novel nanotechnology applications with more radical capabilities and implications are foreseen across the economy, including in aerospace, construction, electronics, environment, medicine, and security.

Congress established the National Nanotechnology Initiative (NNI) to coordinate substantial increases in federally-funded nanotechnology research and infrastructure. Federal investments have been directed mainly to support nanotechnology research centers and projects, with some resources also allocated to education, training, and consideration of environmental, health, and societal implications. Several U.S. states have launched programs to foster nanotechnology development. The new Obama administration is set to further expand America's nanotechnology efforts, with additional federal R&D investment, including in the energy sector. Governments in Europe, China, Japan, and other countries have also greatly expanded their investments in nanotechnology R&D.

Yet, while hopes are high for nanotechnology, what is actually happening on the ground in terms of nanotechnology research and commercialization? In which regions and countries is nanotechnology research clustering, and what is the U.S. position relative to other international competitors? What has been achieved by the $10 billion federal nanotechnology R&D investment since 2001? Are U.S. companies also making long-term investments in nanotechnology, and in what sectors, technologies and locations are corporations focusing upon? Do traditional manufacturing sectors, like textiles or wood products, enabled by new nanotechnology innovation have a place in the new innovation economy? What is the role for new small start-up nanotechnology companies versus larger incumbents? How fast can nanoscience move from laboratory to industry and users, and what policy changes could help speedup nanotech commercialization?

Philip Shapira and Alan Porter of the Center for Nanotechnology in Society (CNS-ASU) will address these questions and more at a March 23rd program with Project on Emerging Nanotechnologies Director David Rejeski.

Shapira, a Professor with the School of Public Policy at Georgia Institute of Technology (Georgia Tech) and the Manchester Business School (England), is a leading expert on technology and innovation processes and policies and their impacts on economic and regional development and industrial competitiveness. Porter, an emeritus professor in industrial and systems engineering and in public policy at Georgia Tech, is internationally recognized for research on technology intelligence, forecasting, and assessment, and for mining electronic, bibliographic data sources to generate intelligence on emerging technologies. Shapira and Porter have collaborated in the development and analysis of large-scale global databases of nanotechnology research and commercialization activities.

To attend this event, RSVP to [email protected]. No RSVP is required to view the Web cast.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.